Clinical Trials · NCT03021187
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 731
- Start date
- Feb 2017
- Locations
- 118 sites, 10 countries
- Primary endpoint
- Change in HbA1c (Week 26)